Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III randomized double-blind active-controlled study of XZ022 injection for prevention of stress ulcer bleeding in critically ill patients
CTR20260717Phase 3Active
- Sponsor
- Shandong New Era Pharmaceutical
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of esomeprazole sodium in upper gastrointestinal bleeding (UGIB), sponsored by Shandong New Era Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
esomeprazole sodium
03
Conditions
upper gastrointestinal bleeding (UGIB)
Beyond the preview
Go deeper on CTR20260717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260717.